Skip to main content
Erschienen in: International Journal of Colorectal Disease 3/2006

01.04.2006 | Case Report

Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn’s disease

verfasst von: Dario Sorrentino, Claudio Avellini, Carlo Alberto Beltrami, Enrico Pasqual, Ester Zearo

Erschienen in: International Journal of Colorectal Disease | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

Although infliximab has been shown to improve the clinical course of Crohn’s disease, its effect on intestinal strictures is controversial. We describe the case of a woman with steroid-resistant colonic Crohn’s disease presenting with intermittent obstruction because of a tight stricture in the splenic flexure. Compared with uninvolved areas, biopsies showed intense edema and inflammatory cell infiltration and immunohistochemistry revealed an excess of TNF-α. Her symptoms responded promptly (CDAI went from 444 to 168) to an infliximab infusion (10 mg kg−1 BW), which also had a dramatic effect on the stricture, now presenting radiologically as a moderate residual, apparently fibrotic, narrowing of the lumen. Endoscopy and histology confirmed the resolution of inflammation and TNF-α virtually disappeared. The patient refused additional infusions and after a few months the disease recurred with features identical to the pre-treatment phase. She then opted for surgery. Histology of the resected strictured colon revealed edema, inflammation, and fibrosis, with TNF-α back to pre-treatment levels. This case indicates that, in the colon, infliximab specifically relieves the TNF-α-mediated inflammatory component of the stricture while having no effect on fibrosis and suggests that the response to infliximab treatment may depend on the nature of the, stricture itself.
Literatur
1.
Zurück zum Zitat Stenson WF (1999) Inflammatory bowel disease. In: Yamada T, Alpers DH, Laine L, Owyang C, Powell DW (eds) Yamada textbook of gastroenterology. Lippincott Williams and Wilkins, Philadelphia, PA, pp 1775–1839 Stenson WF (1999) Inflammatory bowel disease. In: Yamada T, Alpers DH, Laine L, Owyang C, Powell DW (eds) Yamada textbook of gastroenterology. Lippincott Williams and Wilkins, Philadelphia, PA, pp 1775–1839
2.
Zurück zum Zitat Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H (2002) Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology 123:679–688CrossRefPubMed Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H (2002) Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology 123:679–688CrossRefPubMed
3.
Zurück zum Zitat Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA, Rosenstiel P, Albrecht M, Croucher PJ, Seegert D, Nikolaus S, Hampe J, Lengauer T, Pierrou S, Foelsch UR, Mathew CG, Lagerstrom-Fermer M, Schreiber S (2004) Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 36:476–480CrossRefPubMed Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA, Rosenstiel P, Albrecht M, Croucher PJ, Seegert D, Nikolaus S, Hampe J, Lengauer T, Pierrou S, Foelsch UR, Mathew CG, Lagerstrom-Fermer M, Schreiber S (2004) Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 36:476–480CrossRefPubMed
4.
Zurück zum Zitat Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, El Yafi F, Colombel JF, Belaiche J (2003) Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 52:552–557CrossRefPubMed Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, El Yafi F, Colombel JF, Belaiche J (2003) Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 52:552–557CrossRefPubMed
5.
Zurück zum Zitat Geboes KP, Cabooter L, Geboes K (2000) Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis. Acta Gastro-Enterol Belg 63:371–376 Geboes KP, Cabooter L, Geboes K (2000) Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis. Acta Gastro-Enterol Belg 63:371–376
6.
Zurück zum Zitat Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, Present DH, Rutgeerts P, Scholmerich J, Stange EF, Sutherland LR (2002) A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 122:512–530PubMed Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, Present DH, Rutgeerts P, Scholmerich J, Stange EF, Sutherland LR (2002) A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 122:512–530PubMed
7.
Zurück zum Zitat Olaison G, Sjodahl R, Tagesson C (1990) Glucocorticoid treatment in ileal Crohn’s disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 31:325–328PubMed Olaison G, Sjodahl R, Tagesson C (1990) Glucocorticoid treatment in ileal Crohn’s disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 31:325–328PubMed
8.
Zurück zum Zitat Ramboer C, Verhamme M, Dhondt E, Huys S, Van Eygen K, Vermeire L (1995) Endoscopic treatment of stenosis in recurrent Crohn’s disease with balloon dilation combined with local corticosteroid injection. Gastrointest Endosc 42:252–255PubMed Ramboer C, Verhamme M, Dhondt E, Huys S, Van Eygen K, Vermeire L (1995) Endoscopic treatment of stenosis in recurrent Crohn’s disease with balloon dilation combined with local corticosteroid injection. Gastrointest Endosc 42:252–255PubMed
9.
Zurück zum Zitat Van Assche G, Geboes K, Rutgeerts P (2004) Medical therapy for Crohn’s disease strictures. Inflamm Bowel Dis 10:55–60CrossRefPubMed Van Assche G, Geboes K, Rutgeerts P (2004) Medical therapy for Crohn’s disease strictures. Inflamm Bowel Dis 10:55–60CrossRefPubMed
10.
Zurück zum Zitat van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129–135PubMed van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129–135PubMed
11.
Zurück zum Zitat Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337:1029–1035CrossRefPubMed Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337:1029–1035CrossRefPubMed
12.
Zurück zum Zitat Baert FJ, D’Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 116:22–28 Baert FJ, D’Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 116:22–28
13.
Zurück zum Zitat Waetzig GH, Schreiber S (2004) Mechanisms of infliximab: the reverse side of a drug effect. Inflamm Bowel Dis 10:S38–S43CrossRefPubMed Waetzig GH, Schreiber S (2004) Mechanisms of infliximab: the reverse side of a drug effect. Inflamm Bowel Dis 10:S38–S43CrossRefPubMed
14.
Zurück zum Zitat Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ (2004) The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 126:19–31CrossRefPubMed Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ (2004) The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 126:19–31CrossRefPubMed
15.
Zurück zum Zitat D’Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 116:1029–1034PubMed D’Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 116:1029–1034PubMed
16.
Zurück zum Zitat Lichtenstein GR, Olson A, Bao W, Travers S, Diamond RH (2002) Infliximab treatment does not result in an increased risk of intestinal strictures or obstruction in Crohn’s disease patients: accent I study results. Am J Gastroenterol 97:S254CrossRef Lichtenstein GR, Olson A, Bao W, Travers S, Diamond RH (2002) Infliximab treatment does not result in an increased risk of intestinal strictures or obstruction in Crohn’s disease patients: accent I study results. Am J Gastroenterol 97:S254CrossRef
17.
Zurück zum Zitat Keighley MR, Stockbrugger RW (2003) Inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 3):66–70CrossRefPubMed Keighley MR, Stockbrugger RW (2003) Inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 3):66–70CrossRefPubMed
18.
Zurück zum Zitat Gumaste V, Sachar DB, Greenstein AJ (1992) Benign and malignant colorectal strictures in ulcerative colitis. Gut 33:938–941PubMed Gumaste V, Sachar DB, Greenstein AJ (1992) Benign and malignant colorectal strictures in ulcerative colitis. Gut 33:938–941PubMed
19.
Zurück zum Zitat Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N, Gay S, Gay R (1988) Collagen content and types in the intestinal strictures of Crohn’s disease. Gastroenterology 94:257–265PubMed Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N, Gay S, Gay R (1988) Collagen content and types in the intestinal strictures of Crohn’s disease. Gastroenterology 94:257–265PubMed
20.
Zurück zum Zitat Owens MW, Grisham MB (1993) Cytokines increase proliferation of human intestinal smooth muscle cells: possible role in inflammation-induced stricture formation. Inflammation 17:481–487CrossRefPubMed Owens MW, Grisham MB (1993) Cytokines increase proliferation of human intestinal smooth muscle cells: possible role in inflammation-induced stricture formation. Inflammation 17:481–487CrossRefPubMed
21.
Zurück zum Zitat Pucilowska JB, Williams KL, Lund PK (2000) Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol 279:G653–G659 Pucilowska JB, Williams KL, Lund PK (2000) Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol 279:G653–G659
22.
Zurück zum Zitat Zimmermann EM, Li L, Hou YT, Cannon M, Christman GM, Bitar KN (1997) IGF-I induces collagen and IGFBP-5 mRNA in rat intestinal smooth muscle. Am J Physiol 273:G875–G882PubMed Zimmermann EM, Li L, Hou YT, Cannon M, Christman GM, Bitar KN (1997) IGF-I induces collagen and IGFBP-5 mRNA in rat intestinal smooth muscle. Am J Physiol 273:G875–G882PubMed
23.
Zurück zum Zitat Radford-Smith G, Jewell DP (1996) Cytokines and inflammatory bowel disease. Baillière’s Clin Gastroenterol 10:151–164CrossRef Radford-Smith G, Jewell DP (1996) Cytokines and inflammatory bowel disease. Baillière’s Clin Gastroenterol 10:151–164CrossRef
24.
Zurück zum Zitat van Deventer SJ (2001) Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn’s disease. Gastroenterology 121:1242–1246PubMed van Deventer SJ (2001) Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn’s disease. Gastroenterology 121:1242–1246PubMed
25.
Zurück zum Zitat Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, Forbes A, Gassull M, Gendre JP, van Hogezand RA, Lofberg R, Modigliani R, Pallone F, Petritsch W, Prantera C, Rampton D, Seibold F, Vatn M, Zeitz M, Rutgeerts P (2001) BMBF competence network “Inflammatory Bowel disease”. Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001–2003. Int J Colorectal Dis 16:1–11CrossRefPubMed Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, Forbes A, Gassull M, Gendre JP, van Hogezand RA, Lofberg R, Modigliani R, Pallone F, Petritsch W, Prantera C, Rampton D, Seibold F, Vatn M, Zeitz M, Rutgeerts P (2001) BMBF competence network “Inflammatory Bowel disease”. Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001–2003. Int J Colorectal Dis 16:1–11CrossRefPubMed
26.
Zurück zum Zitat Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117:761–769PubMed Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117:761–769PubMed
27.
Zurück zum Zitat Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F (2003) Review article: maintenance treatment of Crohn’s disease. Aliment Pharmacol Ther 17:31–37CrossRefPubMed Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F (2003) Review article: maintenance treatment of Crohn’s disease. Aliment Pharmacol Ther 17:31–37CrossRefPubMed
28.
Zurück zum Zitat Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126:402–413CrossRefPubMed Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126:402–413CrossRefPubMed
29.
Zurück zum Zitat Assche GV (2001) Can we influence fibrosis in Crohn’s disease? Acta Gastro-Enterol Belg 64:193–196 Assche GV (2001) Can we influence fibrosis in Crohn’s disease? Acta Gastro-Enterol Belg 64:193–196
Metadaten
Titel
Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn’s disease
verfasst von
Dario Sorrentino
Claudio Avellini
Carlo Alberto Beltrami
Enrico Pasqual
Ester Zearo
Publikationsdatum
01.04.2006
Erschienen in
International Journal of Colorectal Disease / Ausgabe 3/2006
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-005-0739-0

Weitere Artikel der Ausgabe 3/2006

International Journal of Colorectal Disease 3/2006 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.